Clinical Scorecard: AAO Updates HCQ Retinopathy Guidance

At a Glance

Key Highlights

• Risk of toxicity is less than 1% within 5 years at recommended dosing.
• Annual screening is advised, with baseline screening recommended near treatment initiation.
• Risk of toxicity increases with higher doses and longer duration of use.
• New technologies like AI-based imaging analysis show potential but are not yet validated for routine use.
• Retinopathy detection at mild stages is crucial to prevent progression.

Guideline-Based Recommendations

Diagnosis

• Baseline screening with optical coherence tomography (OCT) and fundus autofluorescence (FAF) is recommended.

Management

• Maintain dosing at no more than 5 mg/kg/day of real body weight.

Monitoring & Follow-up

• Annual screening during therapy; may be deferred for up to 5 years in patients without major risk factors.

Risks

• Increased risk of toxicity in patients with renal disease, older age at treatment initiation, or concurrent use of tamoxifen.

Patient & Prescribing Data

Patients receiving hydroxychloroquine for chronic conditions.

With proper dosing and screening, most patients can safely use HCQ for decades.

Clinical Best Practices

• Utilize OCT and FAF as primary screening tools.
• Implement annual monitoring for long-term HCQ users.
• Educate patients on the importance of adherence to dosing and screening recommendations.

References

• Ophthalmology